Efficacy and safety of immune checkpoint blockade for brain metastases.
作者信息
Harary Maya, Reardon David A, Iorgulescu J Bryan
机构信息
Harvard Medical School, Boston, MA, 02215, USA.
Department of Neurosurgery, Computational Neuroscience Outcomes Center, Brigham & Women's Hospital, Boston, MA, 02215, USA.
出版信息
CNS Oncol. 2019 Jun;8(2):CNS33. doi: 10.2217/cns-2018-0018. Epub 2019 Mar 11.
Abstract
摘要
相似文献
1
Efficacy and safety of immune checkpoint blockade for brain metastases.免疫检查点阻断治疗脑转移瘤的疗效与安全性。
CNS Oncol. 2019 Jun;8(2):CNS33. doi: 10.2217/cns-2018-0018. Epub 2019 Mar 11.
2
Atypical autoimmune adverse effects with checkpoint blockade therapies.检查点阻断疗法的非典型自身免疫不良反应。
Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658.
3
Immune checkpoint inhibitors.免疫检查点抑制剂。
J Cell Biol. 2019 Mar 4;218(3):740-741. doi: 10.1083/jcb.201810035. Epub 2019 Feb 13.
4
Checkpoint blockade after kidney transplantation.肾移植后的检查点阻断
Eur J Cancer. 2018 Jun;96:111-114. doi: 10.1016/j.ejca.2018.03.019. Epub 2018 Apr 26.
5
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.免疫肿瘤学的下一步：通过适当的患者选择和合理设计的联合策略增强抗肿瘤效果。
Ann Oncol. 2017 Jan 1;28(1):57-74. doi: 10.1093/annonc/mdw534.
6
Recent advances in the clinical development of immune checkpoint blockade therapy.免疫检查点阻断疗法的临床开发进展。
Cell Oncol (Dordr). 2019 Oct;42(5):609-626. doi: 10.1007/s13402-019-00456-w. Epub 2019 Jun 14.
7
Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.靶向多个受体以提高检查点阻断疗效。
Int J Mol Sci. 2019 Jan 4;20(1):158. doi: 10.3390/ijms20010158.
8
The next generation of immunotherapy: keeping lung cancer in check.下一代免疫疗法：控制肺癌
J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5.
9
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.癌症的免疫检查点阻断疗法：FDA 批准的免疫检查点抑制剂概述。
Int Immunopharmacol. 2018 Sep;62:29-39. doi: 10.1016/j.intimp.2018.06.001. Epub 2018 Jul 2.
10
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.非小细胞肺癌脑转移患者的免疫治疗。了解脑肿瘤微环境并剖析临床免疫检查点阻断治疗的结果。
Cancer Treat Rev. 2020 Sep;89:102067. doi: 10.1016/j.ctrv.2020.102067. Epub 2020 Jul 7.
引用本文的文献
1
Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.在同种小鼠 CT2A 肿瘤模型中，抗原呈递缺陷、间充质分化和对免疫治疗的抵抗。
Front Immunol. 2023 Dec 28;14:1297932. doi: 10.3389/fimmu.2023.1297932. eCollection 2023.
2
High-dose bevacizumab for radiation-induced brain necrosis: a case report.大剂量贝伐珠单抗治疗放射性脑坏死：一例报告。
CNS Oncol. 2023 Sep 1;12(3):CNS98. doi: 10.2217/cns-2023-0002. Epub 2023 May 4.
3
Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.在抗 PD-1 时代，一线免疫检查点抑制剂的使用与转移性黑色素瘤患者的总生存相关。
JAMA Netw Open. 2022 Aug 1;5(8):e2225459. doi: 10.1001/jamanetworkopen.2022.25459.
4
Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer.非小细胞肺癌治疗期间放射性肺炎联合免疫治疗的研究进展
Cancer Manag Res. 2022 Aug 13;14:2469-2483. doi: 10.2147/CMAR.S374648. eCollection 2022.
5
MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression.MCP-1/CCR2 轴抑制使脑微环境对黑色素瘤脑转移进展敏感。
JCI Insight. 2022 Sep 8;7(17):e154804. doi: 10.1172/jci.insight.154804.
6
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.定义免疫检查点抑制剂治疗的独特临床特征。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003024.
7
Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases.利用纳米医学增强乳腺癌脑转移的免疫治疗。
Drug Deliv Transl Res. 2021 Dec;11(6):2344-2370. doi: 10.1007/s13346-021-01039-9. Epub 2021 Oct 30.
8
Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications.PD-L1 表达与非小细胞肺癌患者初始脑转移的相关性及其临床意义。
Thorac Cancer. 2021 Aug;12(15):2143-2150. doi: 10.1111/1759-7714.14006. Epub 2021 Jun 13.
9
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.免疫检查点抑制剂在不同转移情况的晚期非小细胞肺癌患者中的疗效。
Ann Transl Med. 2021 Jan;9(1):34. doi: 10.21037/atm-20-1471.
10
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors.接受PD-(L)1抑制剂治疗的寡进展性非小细胞肺癌
Cancers (Basel). 2020 Apr 23;12(4):1046. doi: 10.3390/cancers12041046.
本文引用的文献
1
Acquired mechanisms of immune escape in cancer following immunotherapy.免疫治疗后癌症中获得性免疫逃逸机制。
Genome Med. 2018 Nov 22;10(1):87. doi: 10.1186/s13073-018-0598-2.
2
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.在一项 II 期临床试验中，接受派姆单抗治疗的有活性脑转移的黑色素瘤患者的长期生存情况。
J Clin Oncol. 2019 Jan 1;37(1):52-60. doi: 10.1200/JCO.18.00204. Epub 2018 Nov 8.
3
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data.立体定向放射外科和免疫检查点抑制剂治疗脑转移瘤：一项国际单患者数据荟萃分析。
Radiother Oncol. 2019 Jan;130:104-112. doi: 10.1016/j.radonc.2018.08.025. Epub 2018 Sep 18.
4
Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.转移性黑色素瘤的治疗：在批准检查点阻断免疫疗法和靶向治疗后，国家队列的生存率得到提高。
Cancer Immunol Immunother. 2018 Dec;67(12):1833-1844. doi: 10.1007/s00262-018-2241-x. Epub 2018 Sep 6.
5
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.纳武利尤单抗联合伊匹单抗治疗脑转移黑色素瘤。
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.
6
Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.免疫检查点阻断治疗时代黑素瘤脑转移的风险调整后生存率提高：一项全国性队列研究的结果。
Cancer Immunol Res. 2018 Sep;6(9):1039-1045. doi: 10.1158/2326-6066.CIR-18-0067. Epub 2018 Jul 12.
7
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.纳武利尤单抗治疗转移性肾细胞癌的安全性和疗效：扩展准入计划的真实世界结果。
BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.
8
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药治疗黑色素瘤脑转移瘤：一项多中心随机 2 期研究。
Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.
9
Cancer immunotherapy using checkpoint blockade.使用免疫检查点阻断的癌症免疫疗法。
Science. 2018 Mar 23;359(6382):1350-1355. doi: 10.1126/science.aar4060. Epub 2018 Mar 22.
10
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.同步免疫检查点抑制剂和立体定向放射外科治疗非小细胞肺癌、黑色素瘤和肾细胞癌的脑转移。
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):916-925. doi: 10.1016/j.ijrobp.2017.11.041. Epub 2017 Dec 5.
Zotero 插件